Immuto Scientific

Immuto Scientific is a private, pre-clinical stage biotech targeting cancer through a revolutionary focus on disease-specific Surface Protein Conformations (SPCs). Its core asset is a patented, integrated platform combining native-state structural proteomics, ultrasensitive mass spectrometry, and AI/ML to discover novel, targetable epitopes with high disease specificity. The company is pre-revenue and appears to be in the platform validation and early pipeline development phase, positioning itself to unlock a new class of precision therapeutics against previously undruggable targets.

Patented, AI-enabled, high-throughput platform integrating native-state structural proteomics, ultrasensitive mass spectrometry, and machine learning to characterize the disease-specific structural surfaceome and identify novel targetable epitopes (Surface Protein Conformations).

Competes with other AI-driven drug discovery platforms (e.g., Recursion, Exscientia) and structural biology-focused companies, but its unique focus on native-state, disease-specific surface protein conformations provides a differentiated niche. Traditional proteomics companies and large pharma internal efforts also represent competition for target discovery.